BioCentury
ARTICLE | Clinical News

cAd-EBOZ: Phase II/III started

February 23, 2015 8:00 AM UTC

The National Institute of Allergy and Infectious Diseases (NIAID) began the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial to evaluate a single injection of cAd-EBOZ or VSV-ZEB...